Powered by
Canadian-Related Releases

Antibe Therapeutics Reports On Results of AGM Voting

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders of the Corporation held on September 30, 2013.

The matters voted upon at the meeting and the results of the voting were as follows:

Item 1: Election of Directors

On a vote by ballot, each of the five nominees proposed by management was elected to serve as a director of the Corporation and to hold office for the ensuing year or until a successor is elected or appointed. The directors are:

John Wallace
Dan Legault
Walt Macnee
Jonathan Goodman
Rod Flower

Item 2: Appointment of Auditors

On a vote by way of a show of hands, Zeifmans LLP, Chartered Accountants, were appointed the auditors of the Company for the ensuing year at a remuneration to be fixed by the directors of the Company.

About Antibe Therapeutics Inc.

Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. These improvements are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, which are chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Corporation’s drug design methodologies involve chemically linking an existing off-patent drug (“base drug”) to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation, pain or vascular dysfunction, the Corporation’s methodologies can efficiently produce improved versions of a number of existing drugs. Notably, Antibe’s products are themselves fully patent-protectable and benefit from the predictable toxicity and effectiveness profiles of the base drug.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Antibe Therapeutics Inc.
Dan Legault, (416) 473 4095
Chief Executive Officer

Company Information Center

Antibe Therapeutics Inc. RSS feed for Antibe Therapeutics Inc.


ISIN: CA0370251039